panitumumab
amgen,takeda
['congrat', 'paradigm']
fantastic to see the result of paradigm trial as a first lba in the asco plenary session presented by dr. yoshino. congrats japanese collaborators and patients. no pfs differences and crossover in km curve still need to be discussed but definitely a practice changer. #asco22 
????? IM resident @MountSinaiNYC from Japan. Aspiring med-onc physician scientist. Interested in drug development. Dog lover. Tweets are my own.